Early trial tests new weapon against tough cancers
NCT ID NCT03564691
Summary
This was a first-in-human study to test the safety and early signs of effectiveness of a new drug called MK-4830. It was given alone and in combination with an existing immunotherapy (pembrolizumab) to 470 people with various advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe dose levels and see if the treatment caused tumors to shrink.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancercare Rondebosch Oncology ( Site 0210)
Cape Town, Western Cape, 7700, South Africa
-
Centre Hospitalier Universitaire de Poitiers ( Site 2000)
Poitiers, Vienne, 86000, France
-
Centre Oscar Lambret ( Site 2002)
Lille, Nord, 59000, France
-
Centro Integral Oncologico Clara Campal START Madrid ( Site 0102)
Madrid, 28050, Spain
-
Chaim Sheba Medical Center. ( Site 0044)
Ramat Gan, 5265601, Israel
-
Euromedica General Clinic of Thessaloniki-Oncology Unit ( Site 0112)
Thessaloniki, 546 45, Greece
-
European Interbalkan Medical Center ( Site 0111)
Thessaloniki, 57001, Greece
-
Henry Ford Health System ( Site 0002)
Detroit, Michigan, 48202, United States
-
Hôpital Européen Georges Pompidou ( Site 2003)
Paris, Île-de-France Region, 75015, France
-
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0101)
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Japanese Foundation for Cancer Research ( Site 0401)
Tokyo, 135-8550, Japan
-
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)
Hackensack, New Jersey, 07601, United States
-
Juravinski Cancer Centre ( Site 0034)
Hamilton, Ontario, L8V 5C2, Canada
-
Laura and Isaac Perlmutter Cancer Center ( Site 0008)
New York, New York, 10016, United States
-
Liverpool Hospital-Medical Oncology ( Site 0250)
Liverpool, New South Wales, 2170, Australia
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warsaw, Masovian Voivodeship, 02-781, Poland
-
National Cancer Center Hospital East ( Site 0400)
Kashiwa, Chiba, 2778577, Japan
-
Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 00
Columbus, Ohio, 43210, United States
-
Princess Alexandra Hospital ( Site 0253)
Brisbane, Queensland, 4102, Australia
-
Princess Margaret Cancer Centre ( Site 0033)
Toronto, Ontario, M5G 2M9, Canada
-
Rabin Medical Center ( Site 0043)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus-Oncology Division ( Site 0042)
Haifa, 3109601, Israel
-
Seattle Cancer Care Alliance ( Site 0010)
Seattle, Washington, 98109, United States
-
Severance Hospital Yonsei University Health System ( Site 0300)
Seoul, 03722, South Korea
-
Shanghai Chest Hospital-Oncology department ( Site 0801)
Shanghai, Shanghai Municipality, 200030, China
-
Sourasky Medical Center ( Site 0041)
Tel Aviv, 6423906, Israel
-
South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)
San Antonio, Texas, 78229, United States
-
The First Hospital of Jilin University ( Site 0803)
Changchun, Jilin, 130021, China
-
The Oncology Centre ( Site 0212)
Durban, KwaZulu-Natal, 4091, South Africa
-
The Ottawa Hospital ( Site 0031)
Ottawa, Ontario, K1H 8L6, Canada
-
University General Hospital of Heraklion ( Site 0110)
Heraklion, Irakleio, 711 10, Greece
-
University of California at San Francisco ( Site 0004)
San Francisco, California, 94158, United States
-
Uniwersyteckie Centrum Kliniczne ( Site 0151)
Gdansk, Pomeranian Voivodeship, 80-214, Poland
-
Utah Cancer Specialists ( Site 0011)
Salt Lake City, Utah, 84106, United States
-
Washington University ( Site 0003)
St Louis, Missouri, 63110, United States
-
West China Hospital of Sichuan University ( Site 0804)
Chengdu, Sichuan, 610041, China
-
Wits Clinical Research ( Site 0213)
Johannesburg, Gauteng, 2193, South Africa
Conditions
Explore the condition pages connected to this study.